Prevention and management of adverse events during treatment with bispecific antibodies and CART cells in multiple myeloma: a consensus report of the European Myeloma Network
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F23%3AE0110280" target="_blank" >RIV/00843989:_____/23:E0110280 - isvavai.cz</a>
Alternative codes found
RIV/61988987:17110/23:A2402L3F
Result on the web
<a href="https://www.sciencedirect.com/science/article/pii/S1470204523001596?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/pii/S1470204523001596?via%3Dihub</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/S1470-2045(23)00159-6" target="_blank" >10.1016/S1470-2045(23)00159-6</a>
Alternative languages
Result language
angličtina
Original language name
Prevention and management of adverse events during treatment with bispecific antibodies and CART cells in multiple myeloma: a consensus report of the European Myeloma Network
Original language description
T-cell redirecting bispecific antibodies (BsAbs) and chimeric antigen receptor T cells (CAR T cells) have revolutionised multiple myeloma therapy, but adverse events such as cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome (ICANS), cytopenias, hypogammaglobulinaemia, and infections are common. This Policy Review presents a consensus from the European Myeloma Network on the prevention and management of these adverse events. Recommended measures include premedication, frequent assessing for symptoms and severity of cytokine release syndrome, step-up dosing for several BsAbs and some CAR T-cell therapies; corticosteroids; and tocilizumab in the case of cytokine release syndrome. Other anti-IL-6 drugs, high-dose corticosteroids, and anakinra might be considered in refractory cases. ICANS often arises concomitantly with cytokine release syndrome. Glucocorticosteroids in increasing doses are recommended if needed, as well as anakinra if the response is inadequate, and anticonvulsants if convulsions occur. Preventive measures against infections include antiviral and antibacterial drugs and administration of immunoglobulins. Treatment of infections and other complications is also addressed.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Lancet Oncology
ISSN
1470-2045
e-ISSN
1474-5488
Volume of the periodical
24
Issue of the periodical within the volume
6
Country of publishing house
US - UNITED STATES
Number of pages
1
Pages from-to
e255-e269
UT code for WoS article
001019600600001
EID of the result in the Scopus database
2-s2.0-85160434590